drugset / Trial / NCT02905318

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02905318 ↗

Phase 2 Active not recruiting 19 enrolled Canadian Cancer Trials Group Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib. The researchers doing this study are also interested in looking for markers that may help predict which patients are most likely to be helped by palbociclib and to see how the cancer cells respond to palbociclib.

Timeline

Start
2017-07-04
Primary completion
2022-04-29
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 125 mg Oral

Indications